Zhou J - Search Results

1

Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.

Zhou J, Bi C, Ching YQ, Chooi JY, Lu X, Quah JY, Toh SH, Chan ZL, Tan TZ, Chong PS, Chng WJ. Zhou J, et al. J Hematol Oncol. 2017 Jul 11;10(1):138. doi: 10.1186/s13045-017-0507-y. J Hematol Oncol. 2017. PMID: 28693523 Free PMC article.

2

Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling.

Shen J, Tai YC, Zhou J, Stephen Wong CH, Cheang PT, Fred Wong WS, Xie Z, Khan M, Han JH, Chen CS. Shen J, et al. Among authors: zhou j. Exp Hematol. 2007 Jan;35(1):75-83. doi: 10.1016/j.exphem.2006.09.007. Exp Hematol. 2007. PMID: 17198876 Free article.

3

Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway.

Zhou J, Pan M, Xie Z, Loh SL, Bi C, Tai YC, Lilly M, Lim YP, Han JH, Glaser KB, Albert DH, Davidsen SK, Chen CS. Zhou J, et al. Leukemia. 2008 Jan;22(1):138-46. doi: 10.1038/sj.leu.2404960. Epub 2007 Oct 18. Leukemia. 2008. PMID: 17943175

4

In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor.

Zhou J, Khng J, Jasinghe VJ, Bi C, Neo CH, Pan M, Poon LF, Xie Z, Yu H, Yeoh AE, Lu Y, Glaser KB, Albert DH, Davidsen SK, Chen CS. Zhou J, et al. Leuk Res. 2008 Jul;32(7):1091-100. doi: 10.1016/j.leukres.2007.11.025. Epub 2007 Dec 26. Leuk Res. 2008. PMID: 18160102

5

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H, Glaser KB, Albert DH, Davidsen SK, Chen CS. Zhou J, et al. Blood. 2009 Apr 23;113(17):4052-62. doi: 10.1182/blood-2008-05-156422. Epub 2009 Jan 14. Blood. 2009. PMID: 19144991 Free article.

6

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.

Zhou J, Goh BC, Albert DH, Chen CS. Zhou J, et al. J Hematol Oncol. 2009 Jul 30;2:33. doi: 10.1186/1756-8722-2-33. J Hematol Oncol. 2009. PMID: 19642998 Free PMC article. Review.

7

Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling.

Ng SB, Selvarajan V, Huang G, Zhou J, Feldman AL, Law M, Kwong YL, Shimizu N, Kagami Y, Aozasa K, Salto-Tellez M, Chng WJ. Ng SB, et al. Among authors: zhou j. J Pathol. 2011 Mar;223(4):496-510. doi: 10.1002/path.2823. Epub 2011 Jan 5. J Pathol. 2011. PMID: 21294123

8

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy.

Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, Tay KG, Zeng Q, Li J, Guo K, Tan CP, Yu H, Albert DH, Chen CS. Zhou J, et al. PLoS One. 2011 May 12;6(5):e19798. doi: 10.1371/journal.pone.0019798. PLoS One. 2011. PMID: 21589872 Free PMC article.

9

Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.

Xie Z, Bi C, Cheong LL, Liu SC, Huang G, Zhou J, Yu Q, Chen CS, Chng WJ. Xie Z, et al. Among authors: zhou j. PLoS One. 2011;6(6):e21583. doi: 10.1371/journal.pone.0021583. Epub 2011 Jun 24. PLoS One. 2011. PMID: 21720561 Free PMC article.

10

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ. Zhou J, et al. Blood. 2011 Sep 8;118(10):2830-9. doi: 10.1182/blood-2010-07-294827. Epub 2011 Jul 6. Blood. 2011. PMID: 21734239 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55,193 results

Search Page

Filters